An approach to antiretroviral treatment of HIV disease. Nucleoside monotherapy.
Despite hopes for attack of multiple viral targets, the licensed agents now in use are all of one type: the nucleoside analogue reverse transcriptase inhibitors, of which four, including zidovudine, are available, with a fifth likely to follow. Clinicians and patients are still struggling to learn how best to employ them; but even now, the available trial results can be distilled into rational management plans.
Gunnarsson
G
G
Department of Medicine, New England Deaconess Hospital, Harvard Medical School, Boston, USA.
Hammer
S M
SM
D000998:Antiviral Agents / Q000627:therapeutic use*; D016049:Didanosine / Q000037:antagonists & inhibitors / Q000627:therapeutic use; D015658:HIV Infections / Q000188:drug therapy*; D015497:HIV-1; D006801:Humans; D019259:Lamivudine; D009705:Nucleosides / Q000627:therapeutic use*; D018119:Stavudine / Q000627:therapeutic use; D016047:Zalcitabine / Q000031:analogs & derivatives / Q000037:antagonists & inhibitors / Q000627:therapeutic use; D015215:Zidovudine / Q000037:antagonists & inhibitors / Q000627:therapeutic use
D000998:Antiviral Agents; D009705:Nucleosides; D019259:Lamivudine; D015215:Zidovudine; D016047:Zalcitabine; D018119:Stavudine; D016049:Didanosine